Sorting out Pandora's box: Discerning the dynamic roles of liver microenvironment in oncolytic virus therapy for hepatocellular carcinoma

Frontiers in Oncology

Volumn 4 APR, Issue , 2014, Pages

  Altomonte, Jennifer ^a   Ebert, Oliver ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Hepatocellular carcinoma; Immunotherapy; Liver microenvironment; Oncolytic virus; Viral engineering

Indexed keywords

CISPLATIN; DOXORUBICIN; FLUOROURACIL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MATRIX METALLOPROTEINASE; PACLITAXEL; PEXASTIMOGENE DEVACIREPVEC; SORAFENIB;

ADENOVIRUS; DENDRITIC CELL; DRUG MEGADOSE; DYNAMICS; EXTRACELLULAR MATRIX; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; LIVER CELL CARCINOMA; LIVER TOXICITY; LIVER VENOOCCLUSIVE DISEASE; LOW DRUG DOSE; NATURAL KILLER CELL; NONHUMAN; ONCOLYTIC VIROTHERAPY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT; VIRUS LOAD; VIRUS REPLICATION;

EID: 84901032964     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00085     Document Type: Review

References (117)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer (2010) 127(12):2893-917. doi: 10.1002/ijc.25516.
2. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet (2012) 379(9822):1245-55. doi:10.1016/S0140-6736(11)61347-0.
3. El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology (2008) 134(6):1752-63. doi:10.1053/j.gastro.2008.02.090.
4. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 359(4):378-90. doi:10.1056/NEJMoa0708857.
5. Ebert O, Shinozaki K, Huang TG, Savontaus MJ, Garcia-Sastre A, Woo SLC. Oncolytic vesicular stomatitis virus for treatment of orthotopic hepatocellular carcinoma in immune-competent rats. Cancer Res (2003) 63(13):3605-11.
6. Shinozaki K, Ebert O, Kournioti C, Tai YS, Woo SL. Oncolysis of multifocal hepatocellular carcinoma in the rat liver by hepatic artery infusion of vesicular stomatitis virus. Mol Ther (2004) 9(3):368-76. doi:10.1016/j.ymthe.2003.12.004.
7. Shinozaki K, Ebert O, Woo SL. Eradication of advanced hepatocellular carcinoma in rats via repeated hepatic arterial infusions of recombinant VSV. Hepatology (2005) 41(1):196-203. doi:10.1002/hep.20536.
8. Berasain C, Castillo J, Perugorria MJ, Latasa MU, Prieto J, Avila MA. Inflammation and liver cancer: new molecular links. Ann N Y Acad Sci (2009) 1155:206-21. doi:10.1111/j.1749-6632.2009.03704.x.
9. Nakamoto Y, Guidotti LG, Kuhlen CV, Fowler P, Chisari FV. Immune pathogenesis of hepatocellular carcinoma. J Exp Med (1998) 188(2):341-50. doi:10.1084/jem.188.2.341.
10. Gale M Jr, Foy EM. Evasion of intracellular host defence by hepatitis C virus. Nature (2005) 436(7053):939-45. doi:10.1038/nature04078.
11. Wieland SF, Chisari FV. Stealth and cunning: hepatitis B and hepatitis C viruses. J Virol (2005) 79(15):9369-80. doi:10.1128/JVI.79.15.9369-9380.2005.
12. Paradis V. Histopathology of hepatocellular carcinoma. (Fortschritte der Krebsforschung Progres dans les recherches sur le cancer). Recent Results Cancer Res (2013) 190:21-32. doi:10.1007/978-3-642-16037-0_2.
13. Bilzer M, Roggel F, Gerbes AL. Role of Kupffer cells in host defense and liver disease. Liver Int (2006) 26(10):1175-86. doi:10.1111/j.1478-3231.2006.01342.x.
14. Parker GA, Picut CA. Liver immunobiology. Toxicol Pathol (2005) 33(1):52-62. doi:10.1080/01926230590522365.
15. Khare R, Chen CY, Weaver EA, Barry MA. Advances and future challenges in adenoviral vector pharmacology and targeting. Curr Gene Ther (2011) 11(4):241-58. doi:10.2174/156652311796150363.
16. Manickan E, Smith JS, Tian J, Eggerman TL, Lozier JN, Muller J, et al. Rapid Kupffer cell death after intravenous injection of adenovirus vectors. Mol Ther (2006) 13(1):108-17. doi:10.1016/j.ymthe.2005.08.007.
17. Worgall S, Wolff G, Falck-Pedersen E, Crystal RG. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum Gene Ther (1997) 8(1):37-44. doi:10.1089/hum.1997.8.1-37.
18. Xu Z, Tian J, Smith JS, Byrnes AP. Clearance of adenovirus by Kupffer cells is mediated by scavenger receptors, natural antibodies, and complement. J Virol (2008) 82(23):11705-13. doi:10.1128/JVI.01320-08.
19. Alemany R, Suzuki K, Curiel DT. Blood clearance rates of adenovirus type 5 in mice. J Gen Virol (2000) 81(Pt 11):2605-9.
20. Shashkova EV, Doronin K, Senac JS, Barry MA. Macrophage depletion combined with anticoagulant therapy increases therapeutic window of systemic treatment with oncolytic adenovirus. Cancer Res (2008) 68(14):5896-904. doi:10.1158/0008-5472.CAN-08-0488.
21. Schiedner G, Hertel S, Johnston M, Dries V, van Rooijen N, Kochanek S. Selective depletion or blockade of Kupffer cells leads to enhanced and prolonged hepatic transgene expression using high-capacity adenoviral vectors. Mol Ther (2003) 7(1):35-43. doi:10.1016/S1525-0016(02)00017-5.
22. Kolios G, Valatas V, Kouroumalis E. Role of Kupffer cells in the pathogenesis of liver disease. World J Gastroenterol (2006) 12(46):7413-20. doi:10.3748/wjg.v12.i46.7413.
23. Decker K. Biologically active products of stimulated liver macrophages (Kupffer cells). Eur J Biochem (1990) 192(2):245-61. doi:10.1111/j.1432-1033.1990.tb19222.x.
24. Guidotti LG, Chisari FV. Cytokine-mediated control of viral infections. Virology (2000) 273(2):221-7. doi:10.1006/viro.2000.0442.
25. Melchjorsen J. Learning from the messengers: innate sensing of viruses and cytokine regulation of immunity-clues for treatments and vaccines. Viruses (2013) 5(2):470-527. doi:10.3390/v5020470.
26. Zhang Z, Zhang X, Newman K, Liu X. MicroRNA regulation of oncolytic adenovirus 6 for selective treatment of castration-resistant prostate cancer. Mol Cancer Ther (2012) 11(11):2410-8. doi:10.1158/1535-7163.MCT-12-0157.
27. Ferguson MS, Lemoine NR, Wang Y. Systemic delivery of oncolytic viruses: hopes and hurdles. Adv Virol (2012) 2012:805629. doi:10.1155/2012/805629.
28. Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat Biotechnol (2012) 30(7):658-70. doi:10.1038/nbt.2287.
29. Prestwich RJ, Errington F, Harrington KJ, Pandha HS, Selby P, Melcher A. Oncolytic viruses: do they have a role in anti-cancer therapy? Clin Med Oncol (2008) 2:83-96.
30. Vanderkerken K, Bouwens L, Wisse E. Characterization of a phenotypically and functionally distinct subset of large granular lymphocytes (pit cells) in rat liver sinusoids. Hepatology (1990) 12(1):70-5. doi:10.1002/hep.1840120112.
31. Vermijlen D, Luo D, Froelich CJ, Medema JP, Kummer JA, Willems E, et al. Hepatic natural killer cells exclusively kill splenic/blood natural killer-resistant tumor cells by the perforin/granzyme pathway. J Leukoc Biol (2002) 72(4):668-76.
32. Trinchieri G. Biology of natural killer cells. Adv Immunol (1989) 47:187. doi:10.1016/S0065-2776(08)60664-1.
33. Welsh RM. Regulation of virus infections by natural killer cells. Nat Immun (1986) 5:169-99.
34. Brutkiewicz RR, Welsh RM. Major histocompatibility complex class I antigens and the control of viral infections by natural killer cells. J Virol (1995) 69:3967-71.
35. Baraz L, Khazanov E, Condiotti R, Kotler M, Nagler A. Natural killer (NK) cells prevent virus production in cell culture. Bone Marrow Transplant (1999) 24:179-89. doi:10.1038/sj.bmt.1701825.
36. Vanderkerken K, Bouwens L, De Neve W, Van den Berg K, Baekeland M, Delens N, et al. Origin and differentiation of hepatic natural killer cells (pit cells). Hepatology (1993) 18(4):919-25. doi:10.1002/hep.1840180425.
37. Vanderkerken K, Bouwens L, van Rooijen N, van den Berg K, Baekeland M, Wisse E. The role of Kupffer cells in the differentiation process of hepatic natural killer cells. Hepatology (1995) 22(1):283-90. doi:10.1002/hep.1840220139.
38. Gao B, Radaeva S, Park O. Liver natural killer and natural killer T cells: immunobiology and emerging roles in liver diseases. J Leukoc Biol (2009) 86(3):513-28. doi:10.1189/JLB.0309135.
39. Ishiyama K, Ohdan H, Ohira M, Mitsuta H, Arihiro K, Asahara T. Difference in cytotoxicity against hepatocellular carcinoma between liver and periphery natural killer cells in humans. Hepatology (2006) 43(2):362-72. doi:10.1002/hep.21035.
40. Biron CA, Nguyen KB, Pien GC, Cousens LP, Salazar-Mather TP. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol (1999) 17:189-220. doi:10.1146/annurev.immunol.17.1.189.
41. Biron CA, Brossay L. NK cells and NKT cells in innate defense against viral infections. Curr Opin Immunol (2001) 13:458-64. doi:10.1016/S0952-7915(00)00241-7.
42. Altomonte J, Wu L, Chen L, Meseck M, Ebert O, Garcia-Sastre A, et al. Exponential enhancement of oncolytic vesicular stomatitis virus potency by vector-mediated suppression of inflammatory responses in vivo. Mol Ther (2008) 16(1):146-53. doi:10.1038/sj.mt.6300343.
43. Okuda H. Hepatocellular carcinoma development in cirrhosis. Best Pract Res Clin Gastroenterol (2007) 21(1):161-73. doi:10.1016/j.bpg.2006.07.002.
44. Mazzanti R, Gramantieri L, Bolondi L. Hepatocellular carcinoma: epidemiology and clinical aspects. Mol Aspects Med (2008) 29(1-2):130-43. doi:10.1016/j.mam.2007.09.008.
45. Donato MF, Colombo M, Matarazzo M, Paronetto F. Distribution of basement membrane components in human hepatocellular carcinoma. Cancer (1989) 63(2):272-9. doi:10.1002/1097-0142(19890115)63:2<272::AID-CNCR2820630212>3.0.CO;2-L.
46. Lai KK, Shang S, Lohia N, Booth GC, Masse DJ, Fausto N, et al. Extracellular matrix dynamics in hepatocarcinogenesis: a comparative proteomics study of PDGFC transgenic and Pten null mouse models. PLoS Genet (2011) 7(6):e1002147. doi:10.1371/journal.pgen.1002147.
47. Carloni V, Luong TV, Rombouts K. Hepatic stellate cells and ECM in HCC: more complicated than ever. Liver Int (2014).doi:10.1111/liv.12465.
48. Leonardi GC, Candido S, Cervello M, Nicolosi D, Raiti F, Travali S, et al. The tumor microenvironment in hepatocellular carcinoma (review). Int J Oncol (2012) 40(6):1733-47. doi:10.3892/ijo.2012.1408.
49. Yang JD, Nakamura I, Roberts LR. The tumor microenvironment in hepatocellular carcinoma: current status and therapeutic targets. Semin Cancer Biol (2011) 21(1):35-43. doi:10.1016/j.semcancer.2010.10.007.
50. Guidotti LG, Rochford R, Chung J, Shapiro M, Purcell R, Chisari FV. Viral clearance without destruction of infected cells during acute HBV infection. Science (1999) 284(5415):825-9. doi:10.1126/science.284.5415.825.
51. Rehermann B. Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells. Nat Med (2013) 19(7):859-68. doi:10.1038/nm.3251.
52. Dunn C, Peppa D, Khanna P, Nebbia G, Jones M, Brendish N, et al. Temporal analysis of early immune responses in patients with acute hepatitis B virus infection. Gastroenterology (2009) 137(4):1289-300. doi:10.1053/j.gastro.2009.06.054.
53. Paulsen D, Urban A, Knorr A, Hirth-Dietrich C, Siegling A, Volk HD, et al. Inactivated ORF virus shows antifibrotic activity and inhibits human hepatitis B virus (HBV) and hepatitis C virus (HCV) replication in preclinical models. PLoS One (2013) 8(9):e74605. doi:10.1371/journal.pone.0074605.
54. Weber O, Siegling A, Friebe A, Limmer A, Schlapp T, Knolle P, et al. Inactivated Parapoxvirus ovis (Orf virus) has antiviral activity against hepatitis B virus and herpes simplex virus. J Gen Virol (2003) 84(Pt 7):1843-52. doi:10.1099/vir.0.19138-0.
55. Liu TC, Hwang T, Park BH, Bell J, Kirn DH. The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma. Mol Ther (2008) 16(9):1637-42. doi:10.1038/mt.2008.143.
56. Li YL, Wu J, Wei D, Zhang DW, Feng H, Chen ZN, et al. Newcastle disease virus represses the activation of human hepatic stellate cells and reverses the development of hepatic fibrosis in mice. Liver Int (2009) 29(4):593-602. doi:10.1111/j.1478-3231.2009.01971.x.
57. Altomonte J, Marozin S, De Toni EN, Rizzani A, Esposito I, Steiger K, et al. Antifibrotic properties of transarterial oncolytic VSV therapy for hepatocellular carcinoma in rats with thioacetamide-induced liver fibrosis. Mol Ther (2013) 21(11):2032-42. doi:10.1038/mt.2013.181.
58. Nowatzky J, Knorr A, Hirth-Dietrich C, Siegling A, Volk HD, Limmer A, et al. Inactivated Orf virus (Parapoxvirus ovis) elicits antifibrotic activity in models of liver fibrosis. Hepatol Res (2013) 43(5):535-46. doi:10.1111/j.1872-034X.2012.01086.x.
59. Amann T, Bataille F, Spruss T, Muhlbauer M, Gabele E, Scholmerich J, et al. Activated hepatic stellate cells promote tumorigenicity of hepatocellular carcinoma. Cancer Sci (2009) 100(4):646-53. doi:10.1111/j.1349-7006.2009.01087.x.
60. Ju MJ, Qiu SJ, Fan J, Xiao YS, Gao Q, Zhou J, et al. Peritumoral activated hepatic stellate cells predict poor clinical outcome in hepatocellular carcinoma after curative resection. Am J Clin Pathol (2009) 131(4):498-510. doi:10.1309/AJCP86PPBNGOHNNL.
61. Altomonte J, Ebert O. Replicating viral vectors for cancer therapy: strategies to synergize with host immune responses. Microb Biotechnol (2012) 5(2):251-9. doi:10.1111/j.1751-7915.2011.00296.x.
62. Prestwich RJ, Errington F, Diaz RM, Pandha HS, Harrington KJ, Melcher AA, et al. The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon. Hum Gene Ther (2009) 20(10):1119-32. doi:10.1089/hum.2009.135.
63. Stanford MM, Breitbach CJ, Bell JC, McFadden G. Innate immunity, tumor microenvironment and oncolytic virus therapy: friends or foes? Curr Opin Mol Ther (2008) 10(1):32-7.
64. Irvine KR, Chamberlain RS, Shulman EP, Surman DR, Rosenberg SA, Restifo NP. Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors. J Natl Cancer Inst (1997) 89(21):1595-601. doi:10.1093/jnci/89.21.1595.
65. Ilett EJ, Prestwich RJ, Kottke T, Errington F, Thompson JM, Harrington KJ, et al. Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity. Gene Ther (2009) 16(5):689-99. doi:10.1038/gt.2009.29.
66. Thorne SH, Negrin RS, Contag CH. Synergistic antitumor effects of immune cell-viral biotherapy. Science (2006) 311(5768):1780-4. doi:10.1126/science.1121411.
67. Laga R, Carlisle R, Tangney M, Ulbrich K, Seymour LW. Polymer coatings for delivery of nucleic acid therapeutics. J Control Release (2012) 161(2):537-53. doi:10.1016/j.jconrel.2012.02.013.
68. Alcami A. Viral mimicry of cytokines, chemokines and their receptors. Nat Rev Immunol (2003) 3(1):36-50. doi:10.1038/nri980.
69. Seet BT, McFadden G. Viral chemokine-binding proteins. J Leukoc Biol (2002) 72(1):24-34.
70. Sieben M, Herzer K, Zeidler M, Heinrichs V, Leuchs B, Schuler M, et al. Killing of p53-deficient hepatoma cells by parvovirus H-1 and chemotherapeutics requires promyelocytic leukemia protein. World J Gastroenterol (2008) 14(24):3819-28. doi:10.3748/wjg.14.3819.
71. Li Y, Yu DC, Chen Y, Amin P, Zhang H, Nguyen N, et al. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin. Cancer Res (2001) 61(17):6428-36.
72. Mao CY, Hua HJ, Chen P, Yu DC, Cao J, Teng LS. Combined use of chemotherapeutics and oncolytic adenovirus in treatment of AFP-expressing hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int (2009) 8(3):282-7.
73. Protzer U, Maini MK, Knolle PA. Living in the liver: hepatic infections. Nat Rev Immunol (2012) 12(3):201-13. doi:10.1038/nri3169.
74. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A (1993) 90(8):3539-43. doi:10.1073/pnas.90.8.3539.
75. Huang AY, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science (1994) 264(5161):961-5. doi:10.1126/science.7513904.
76. Janke M, Peeters B, de Leeuw O, Moorman R, Arnold A, Fournier P, et al. Recombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy. Gene Ther (2007) 14(23):1639-49. doi:10.1038/sj.gt.3303026.
77. Cerullo V, Pesonen S, Diaconu I, Escutenaire S, Arstila PT, Ugolini M, et al. Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients. Cancer Res (2010) 70(11):4297-309. doi:10.1158/0008-5472.CAN-09-3567.
78. Kim JH, Oh JY, Park BH, Lee DE, Kim JS, Park HE, et al. Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. Mol Ther (2006) 14(3):361-70. doi:10.1016/j.ymthe.2006.05.008.
79. Liu BL, Robinson M, Han ZQ, Branston RH, English C, Reay P, et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther (2003) 10(4):292-303. doi:10.1038/sj.gt.3301885.
80. Grote D, Cattaneo R, Fielding AK. Neutrophils contribute to the measles virus-induced antitumor effect: enhancement by granulocyte macrophage colony-stimulating factor expression. Cancer Res (2003) 63(19):6463-8.
81. Park BH, Hwang T, Liu TC, Sze DY, Kim JS, Kwon HC, et al. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol (2008) 9(6):533-42. doi:10.1016/S1470-2045(08)70107-4.
82. Heo J, Reid T, Ruo L, Breitbach CJ, Rose S, Bloomston M, et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med (2013) 19(3):329-36. doi:10.1038/nm.3089.
83. Shin EJ, Wanna GB, Choi B, Aguila D III, Ebert O, Genden EM, et al. Interleukin-12 expression enhances vesicular stomatitis virus oncolytic therapy in murine squamous cell carcinoma. Laryngoscope (2007) 117(2):210-4. doi:10.1097/01.mlg.0000246194.66295.d8.
84. Luo J, Xia Q, Zhang R, Lv C, Zhang W, Wang Y, et al. Treatment of cancer with a novel dual-targeted conditionally replicative adenovirus armed with mda-7/IL-24 gene. Clin Cancer Res (2008) 14(8):2450-7. doi:10.1158/1078-0432.CCR-07-4596.
85. Vigil A, Park MS, Martinez O, Chua MA, Xiao S, Cros JF, et al. Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus. Cancer Res (2007) 67(17):8285-92. doi:10.1158/0008-5472.CAN-07-1025.
86. Dong Z, Greene G, Pettaway C, Dinney CP, Eue I, Lu W, et al. Suppression of angiogenesis, tumorigenicity, and metastasis by human prostate cancer cells engineered to produce interferon-beta. Cancer Res (1999) 59(4):872-9.
87. Wirth T, Kuhnel F, Fleischmann-Mundt B, Woller N, Djojosubroto M, Rudolph KL, et al. Telomerase-dependent virotherapy overcomes resistance of hepatocellular carcinomas against chemotherapy and tumor necrosis factor-related apoptosis-inducing ligand by elimination of Mcl-1. Cancer Res (2005) 65(16):7393-402. doi:10.1158/0008-5472.CAN-04-3664.
88. Boozari B, Mundt B, Woller N, Struver N, Gurlevik E, Schache P, et al. Antitumoural immunity by virus-mediated immunogenic apoptosis inhibits metastatic growth of hepatocellular carcinoma. Gut (2010) 59(10):1416-26. doi:10.1136/gut.2009.196519.
89. Altomonte J, Braren R, Schulz S, Marozin S, Rummeny EJ, Schmid RM, et al. Synergistic antitumor effects of transarterial viroembolization for multifocal hepatocellular carcinoma in rats. Hepatology (2008) 48(6):1864-73. doi:10.1002/hep.22546.
90. Wu L, Huang TG, Meseck M, Altomonte J, Ebert O, Shinozaki K, et al. rVSV(M Delta 51)-M3 is an effective and safe oncolytic virus for cancer therapy. Hum Gene Ther (2008) 19(6):635-47. doi:10.1089/hum.2007.163.
91. Altomonte J, Wu L, Meseck M, Chen L, Ebert O, Garcia-Sastre A, et al. Enhanced oncolytic potency of vesicular stomatitis virus through vector-mediated inhibition of NK and NKT cells. Cancer Gene Ther (2009) 16(3):266-78. doi:10.1038/cgt.2008.74.
92. Wada Y, Nakashima O, Kutami R, Yamamoto O, Kojiro M. Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration. Hepatology (1998) 27(2):407-14. doi:10.1002/hep.510270214.
93. Greten TF, Manns MP, Korangy F. Immunotherapy of hepatocellular carcinoma. J Hepatol (2006) 45(6):868-78. doi:10.1016/j.jhep.2006.09.004.
94. Greten TF, Manns MP, Korangy F. Immunotherapy of HCC. Rev Recent Clin Trials (2008) 3(1):31-9. doi:10.2174/157488708783330549.
95. Greten TF, Duffy AG, Korangy F. Hepatocellular carcinoma from an immunologic perspective. Clin Cancer Res (2013) 19(24):6678-85. doi:10.1158/1078-0432.CCR-13-1721.
96. Lee WC, Wang HC, Hung CF, Huang PF, Lia CR, Chen MF. Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: a clinical trial. J Immunother (2005) 28(5):496-504. doi:10.1097/01.cji.0000171291.72039.e2.
97. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol (1994) 12:991-1045. doi:10.1146/annurev.immunol.12.1.991.
98. Schulz O, Diebold SS, Chen M, Naslund TI, Nolte MA, Alexopoulou L, et al. Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature (2005) 433(7028):887-92. doi:10.1038/nature03326.
99. Kirn DH, Wang Y, Le Boeuf F, Bell J, Thorne SH. Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus. PLoS Med (2007) 4(12):e353. doi:10.1371/journal.pmed.0040353.
100. Saloura V, Wang LC, Fridlender ZG, Sun J, Cheng G, Kapoor V, et al. Evaluation of an attenuated vesicular stomatitis virus vector expressing interferon-beta for use in malignant pleural mesothelioma: heterogeneity in interferon responsiveness defines potential efficacy. Hum Gene Ther (2010) 21(1):51-64. doi:10.1089/hum.2009.088.
101. Brown JL, Barsoum J, Qin XQ. CD4+ T helper cell-independent antitumor response mediated by murine IFN-beta gene delivery in immunocompetent mice. J Interferon Cytokine Res (2002) 22(6):719-28. doi:10.1089/10799900260100222.
102. Su C, Peng L, Sham J, Wang X, Zhang Q, Chua D, et al. Immune gene-viral therapy with triplex efficacy mediated by oncolytic adenovirus carrying an interferon-gamma gene yields efficient antitumor activity in immunodeficient and immunocompetent mice. Mol Ther (2006) 13(5):918-27. doi:10.1016/j.ymthe.2005.12.011.
103. Farrell CJ, Zaupa C, Barnard Z, Maley J, Martuza RL, Rabkin SD, et al. Combination immunotherapy for tumors via sequential intratumoral injections of oncolytic herpes simplex virus 1 and immature dendritic cells. Clin Cancer Res (2008) 14(23):7711-6. doi:10.1158/1078-0432.CCR-08-1364.
104. Kottke T, Diaz RM, Kaluza K, Pulido J, Galivo F, Wongthida P, et al. Use of biological therapy to enhance both virotherapy and adoptive T-cell therapy for cancer. Mol Ther (2008) 16(12):1910-8. doi:10.1038/mt.2008.212.
105. Wongthida P, Diaz RM, Pulido C, Rommelfanger D, Galivo F, Kaluza K, et al. Activating systemic T-cell immunity against self tumor antigens to support oncolytic virotherapy with vesicular stomatitis virus. Hum Gene Ther (2011) 22(11):1343-53. doi:10.1089/hum.2010.216.
106. Gonzalez-Carmona MA, Marten A, Hoffmann P, Schneider C, Sievers E, Schmidt-Wolf IG, et al. Patient-derived dendritic cells transduced with an A-fetoprotein-encoding adenovirus and co-cultured with autologous cytokine-induced lymphocytes induce a specific and strong immune response against hepatocellular carcinoma cells. Liver Int (2006) 26(3):369-79. doi:10.1111/j.1478-3231.2005.01235.x.
107. Diaz RM, Galivo F, Kottke T, Wongthida P, Qiao J, Thompson J, et al. Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus. Cancer Res (2007) 67(6):2840-8. doi:10.1158/0008-5472.CAN-06-3974.
108. Song XT. Combination of virotherapy and T-cell therapy: arming oncolytic virus with T-cell engagers. Discov Med (2013) 16(90):261-6.
109. Yu F, Wang X, Guo ZS, Bartlett DL, Gottschalk SM, Song XT. T-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy. Mol Ther (2014) 22(1):102-11. doi:10.1038/mt.2013.240.
110. Fournier P, Schirrmacher V. Oncolytic Newcastle disease virus as cutting edge between tumor and host. Biology (2013) 2(3):936-75. doi:10.3390/biology2030936.
111. Bridle BW, Stephenson KB, Boudreau JE, Koshy S, Kazdhan N, Pullenayegum E, et al. Potentiating cancer immunotherapy using an oncolytic virus. Mol Ther (2010) 18(8):1430-9. doi:10.1038/mt.2010.98.
112. Kottke T, Errington F, Pulido J, Galivo F, Thompson J, Wongthida P, et al. Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumors. Nat Med (2011) 17(7):854-9. doi:10.1038/nm.2390.
113. Power AT, Bell JC. Taming the Trojan horse: optimizing dynamic carrier cell/oncolytic virus systems for cancer biotherapy. Gene Ther (2008) 15(10):772-9. doi:10.1038/gt.2008.40.
114. Qiao J, Wang H, Kottke T, Diaz RM, Willmon C, Hudacek A, et al. Loading of oncolytic vesicular stomatitis virus onto antigen-specific T cells enhances the efficacy of adoptive T-cell therapy of tumors. Gene Ther (2008) 15(8):604-16. doi:10.1038/sj.gt.3303098.
115. Tesfay MZ, Kirk AC, Hadac EM, Griesmann GE, Federspiel MJ, Barber GN, et al. PEGylation of vesicular stomatitis virus extends virus persistence in blood circulation of passively immunized mice. J Virol (2013) 87(7):3752-9. doi:10.1128/JVI.02832-12.
116. Wisse E, Jacobs F, Topal B, Frederik P, De Geest B. The size of endothelial fenestrae in human liver sinusoids: implications for hepatocyte-directed gene transfer. Gene Ther (2008) 15(17):1193-9. doi:10.1038/gt.2008.60.
117. Doronin K, Shashkova EV, May SM, Hofherr SE, Barry MA. Chemical modification with high molecular weight polyethylene glycol reduces transduction of hepatocytes and increases efficacy of intravenously delivered oncolytic adenovirus. Hum Gene Ther (2009) 20(9):975-88. doi:10.1089/hum.2009.028.